GO
Loading...

Medicine

More

  • UPDATE 1-GameStop CEO undergoes surgery for brain tumor Tuesday, 19 Aug 2014 | 12:05 PM ET

    Aug 19- GameStop Corp, the world's largest retailer of videogame products, said Chief Executive Paul Raines underwent an unexpected surgery last week for a small cancerous brain tumor. GameStop also said the six-week treatment period will not interfere with Raines' "continued leadership" of the company.

  • GameStop CEO treated for cancerous brain tumor Tuesday, 19 Aug 2014 | 10:24 AM ET

    NEW YORK— GameStop Corp. said Tuesday that its CEO, Paul Raines, had surgery last week to remove a cancerous brain tumor. The prognosis for a full recovery is "very good," GameStop said in a filing with the Securities and Exchange Commission.

  • GameStop CEO undergoes surgery for brain tumor Tuesday, 19 Aug 2014 | 9:52 AM ET

    Aug 19- GameStop Corp, the world's largest retailer of videogame products, said Chief Executive Paul Raines underwent an unexpected surgery last week for a small cancerous brain tumor. Raines, who will be undergoing chemotherapy, will restrict his travel during the expected six week of treatment, the company said in a regulatory filing on Tuesday.

  • The epidemic of the hemorrhagic disease, which can kill up to 90 percent of those it infects, is ravaging the three small West African states of Liberia, Sierra Leone and Guinea, and also has a toehold in Nigeria, Africa's biggest economy. Between Aug. 14-16, Liberia recorded the most new deaths, 53, followed by Sierra Leone with 17, and Guinea with 14..

  • ALS raises over $13 million since July 29th     Monday, 18 Aug 2014 | 6:25 AM ET

    CNBC's Andrew Ross Sorkin looks back on some of the best ice bucket challenge videos from last week, including from Bill Gates, saying the campaign has now hit China.

  • FDA approves Biogen's MS drug Plegridy Friday, 15 Aug 2014 | 7:27 PM ET

    CAMBRIDGE, Mass.— Biogen Idec says that federal regulators have approved the specialty drugmaker's new treatment for people with relapsing forms of multiple sclerosis.

  • Aug 15- Achillion Pharmaceuticals Inc said all patients treated with its experimental hepatitis C drug showed no detectable levels of the virus four weeks after the therapy, sending its shares up 18 percent. Achievement of 100 percent cure rate confirms the competitive profile of NS5A, Wells Fargo Securities analyst Brian Abrahams wrote in a note.

  • FDA clears Avastin for late-stage cervical cancer Friday, 15 Aug 2014 | 10:44 AM ET

    WASHINGTON— The Food and Drug Administration has approved Genentech's Avastin for a new use against late-stage cervical cancer, the seventh indication for the blockbuster biotech drug. The FDA approved the drug late Thursday for women with cervical cancer that is persistent, recurrent or has spread to other parts of the body.

  • Achillion rises on hepatitis C drug study Friday, 15 Aug 2014 | 9:05 AM ET

    NEW YORK— Achillion Pharmaceuticals climbed in premarket trading Friday after the company reported promising results from a small clinical trial of an experimental hepatitis C drug. Shares of Achillion Pharmaceuticals Inc. jumped $1.55, or 18.4 percent, to $9.99 in premarket trading about 30 minutes before the market opening.

  • Aug 15- Achillion Pharmaceuticals Inc said interim results from a mid-stage trial showed that all patients given its experimental hepatitis C drug showed no detectable levels of the virus four weeks after completing the therapy.

  • ALS stunned by millions of dollars     Friday, 15 Aug 2014 | 7:36 AM ET
    Jim Cramer of CNBC takes the Ice Bucket Challenge.

    Lance Slaughter from the ALS Association, discusses the phenomenon spreading across social media to dump a bucket of ice over your head to raise awareness for ALS.

  • Aug 15- Acura Pharmaceuticals Inc said the U.S. Food and Drug Administration indicated that the company may have to conduct an additional study to determine the abuse-deterrent capability of its experimental painkiller treatment. The FDA in May said data was insufficient to support the company's claim that the drug could not be abused by snorting.

  • What is ALS?     Friday, 15 Aug 2014 | 7:32 AM ET

    CNBC's Meg Tirrell explains what ALS, or Lou Gehrig's disease is, and what is known about treating the disease.

  • Is climate change key to the spread of Ebola? Friday, 15 Aug 2014 | 5:56 AM ET
    Women washing along the Niger River near Babila, Guinea.

    Ebola outbreaks may become more frequent because of climate change, scientists warn, as the deadly disease ravages West Africa.

  • Ebola puts focus on drugs made in tobacco plants Friday, 15 Aug 2014 | 1:36 AM ET

    NEW YORK— It's an eye-catching angle in the story of an experimental treatment for Ebola: The drug comes from tobacco plants that were turned into living pharmaceutical factories. "It's definitely not something you smoke," said Jean-Luc Martre, a spokesman for Medicago, a Canadian company that's testing flu vaccines made with tobacco plants.

  • Ebola toll much higher than first thought: WHO Thursday, 14 Aug 2014 | 8:13 PM ET

    Staff with the World Health Organization battling an Ebola outbreak in West Africa see evidence the numbers of reported cases and deaths vastly underestimates the scale of the outbreak.

  • *Guinea declares health emergency over virus. CONAKRY, Aug 14- Staff with the World Health Organization battling an Ebola outbreak in West Africa see evidence the numbers of reported cases and deaths vastly underestimates the scale of the outbreak, the U.N. agency said on its website on Thursday.

  • *US orders embassy family members to leave Sierra Leone. An estimated 377 people have died in Guinea since the world's worst outbreak of Ebola began in March in remote parts of a border region near Sierra Leone and Liberia.

  • Aug 13- Amgen Inc's Kyprolis drug failed to show it could extend survival compared to standard care for patients with advanced multiple myeloma, a type of blood cancer that develops in the bone marrow. Shares of Amgen were down 2.1 percent at $124.66 in after-hours trading on Wednesday.

  • Aug 13- A Phase 3 trial of Amgen Inc's Kyprolis drug failed to show it could extend survival compared to standard care for patients with advanced multiple myeloma, a type of blood cancer that develops in the bone marrow. Shares of Amgen were down 2.3 percent at $124.41 in after-hours trading on Wednesday.